• Hoth Therapeutics on April 13, 2026 announced positive preclinical results from its HT-VA study run under a CRADA with US Department of Veterans Affairs and Emory University.
• Results have already been presented as part of this announcement, with data showing GDNF shifted liver fat handling in a MAFLD model toward less fat formation and more fat burning.
• GDNF outperformed semaglutide on key liver gene-expression markers tied to fat regulation, supporting a potentially differentiated position versus GLP-1 therapies.
• Program broadens Hoth focus into MAFLD/NASH and obesity, with management framing it as a potential disease-modifying approach rather than a weight-loss-only effect.
• Next steps include additional preclinical validation, assessment of clinical development paths in metabolic and liver disease, strategic partnering discussions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hoth Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604131723PR_NEWS_USPR_____NY33292) on April 13, 2026, and is solely responsible for the information contained therein.